All News
Faith and Miracle Larry
This week on the podcast, Dr. Jack Cush recalls what life was like early on during COVID, from March to June of 2020. During this time, his close friend, Larry, contracted COVID-19 and was hospitalized, intubated and put on mechanical ventilation for nearly 2 months.
Read Article
2022 EULAR Recommendations for ANCA-associated Vasculitis
EULAR has published the 2022 update on recommendations for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Read Article
Polypharmacy Increased in Psoriatic Arthritis
Psoriatic arthritis (PsA) is plagued by obesity, depression and increased comorbidities; now it appears that polypharmacy adds to the burden of managing PsA.
Read Article
How do you prevent RA in at-risk patient?
Smoking cessation! Healthy weight and exercise! Diet! Periodontal health! 🚭🏋️🥕🦷
Education & follow-up!
Not robustly proven to prevent/delay RA, but may be more important than early DMARD intervention!
Kevin Deane, MD
#RNL2023 @RheumNow
Eric Dein ericdeinmd ( View Tweet)
Natural history of RA by Kevin Deane #RLN23 @RheumNow https://t.co/ab0cafDblz
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
The amazing JAKs
The many JAK/TYK targets approved for multiple conditions
Coming soon: UPA for Crohn's - first indication for Crohn's disease
#RNL2023 @RheumNow https://t.co/Pf3gzrdyeq
Eric Dein ericdeinmd ( View Tweet)
Dr. Stanley Cohen on JAKinibs:
Very concise and informative timeline on the multiple JAKinibs approved for multiple conditions
@RheumNow #RNL2023 https://t.co/3ZZHr0akrR
Robert B Chao, MD doctorRBC ( View Tweet)
JAKi cycling, likely something we all do/consider in clinic. Dr. S. Cohen reviews the JAK-pot study which shows good, expected results between cycling in patients. #RNL2023 @RheumNow https://t.co/qBau79o0VQ
Dr. Rachel Tate uptoTate ( View Tweet)
About to get my learnin' on! #RNL2023 @RheumNow
Robert B Chao, MD doctorRBC ( View Tweet)
#RNL2023 is up and running! Join us online! @RheumNow https://t.co/AGbpEjXSh6
Dr. Rachel Tate uptoTate ( View Tweet)
Follow me today and tomorrow for @RheumNow Live 2023 Coverage!
#RheumTwitter #RNL2023 https://t.co/sS6AoF1Dij
Eric Dein ericdeinmd ( View Tweet)
QD Clinic - RheumNow Live 2023 Preview https://t.co/T8VMyrL1Qz https://t.co/E90wsaqwaY
Links:
Dr. John Cush RheumNow ( View Tweet)
A Pilot Trial of Anifrolumab in Discoid Lupus
A research report in JAMA Dermatology describes the use of the type 1 interferon receptor inhibitor anifrolumab in patients with chronic discoid lupus erythematosus (DLE).
https://t.co/sax8iHuljb https://t.co/71zqAzZViV
Links:
Dr. John Cush RheumNow ( View Tweet)
Itaconate - A Potential New Immunosuppressive
Researchers have revealed the modulatory effect of the anti-inflammatory metabolite ITA on T helper and T regulatory cells, which may lead to new therapeutic approaches to treating some autoimmune diseases.
https://t.co/1kaxHou8pz https://t.co/VLLAzgiYoM
Links:
Dr. John Cush RheumNow ( View Tweet)
Happy Match Day! Congratulations to all that have matched. #MATCHDAY2023
Dr. John Cush RheumNow ( View Tweet)
Follow my coverage tomorrow and Sunday!
#RNL2023 RheumNow Live
@RheumNow #RheumTwitter https://t.co/6cZHJxPltA
Eric Dein ericdeinmd ( View Tweet)
Multicenter study of 1516 MIS-C pts - Initial Rx: 13% recv anakinra (w/ or w/o) otherdrugs; 64% rx w/ IVIG & steroids, 16%IVIG alone, 4% steroids alone. Anakinra gave no short-term CV benefits over IVIG and glucocorticoids alone. https://t.co/IVaC5dXzs8
Links:
Dr. John Cush RheumNow ( View Tweet)
28 biomarkers studied in 259 SSc-ILD, 179 SSc-NO ILD, 172 IPF & 30 healthy controls. Composite biomarker index (w/ SP-D [surfactant prot. D], Ca15-3 [MUC1], & ICAM-1) strongly correlated w/ SSc-ILD (adj OR 12.7); independent of age, sex, smoking, PFTs https://t.co/F0iKFqcZoY https://t.co/Ao25N1DFIx
Links:
Dr. John Cush RheumNow ( View Tweet)
Transcriptomic studies of Rx Refractory #RA pts shows increased gene expression of plasmacytoid dendritic cells (pDC) (reflecting expansion of pDC precursors) correlated well w/ Rx resistance. Type I IFN negatively correlated w pre-DC gene expression https://t.co/japvTnuTNu https://t.co/ad6ofbg3cO
Links:
Dr. John Cush RheumNow ( View Tweet)
Open-label trial of Guselkumab (IL-23 inhib) in 20 moderate-to-severe hidradenitis suppurativa (HS) pts saw 65% with HiSCR response at wk 16. Yet phase IIB NOVA PBO-RCT showed GUS HiSCR response 45–51% (vs 39% PBO). GUS may only benefit subgroup of HS https://t.co/OxtFfyRMFk https://t.co/hnQyU0VWxg
Links:
Dr. John Cush RheumNow ( View Tweet)